Loading...
XSHE002317
Market cap1.31bUSD
Jan 15, Last price  
11.43CNY
1D
2.55%
1Q
-4.35%
Jan 2017
-5.59%
IPO
23.36%
Name

Guangdong Zhongsheng Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHE:002317 chart
P/E
35.82
P/S
3.61
EPS
0.32
Div Yield, %
1.82%
Shrs. gr., 5y
0.02%
Rev. gr., 5y
2.03%
Revenues
2.61b
-2.45%
326,896,741404,403,391484,305,049551,602,812640,714,827750,643,827886,433,2231,090,027,7021,308,516,5031,577,736,5931,692,485,8231,964,235,0012,361,506,4462,531,516,4391,895,823,5602,429,095,4632,676,151,6172,610,550,120
Net income
263m
-18.25%
31,882,31742,266,10274,384,148100,354,725131,510,099150,537,489181,511,696187,702,279224,562,067296,714,725414,369,019420,121,093435,648,315317,729,4690277,631,096322,050,284263,273,179
CFO
191m
+202.23%
17,907,33449,354,64572,858,784100,891,08791,719,57970,555,422142,379,371110,945,083100,595,091192,248,390338,282,194369,905,148326,781,984251,155,767138,932,206622,766,28863,069,779190,613,632
Dividend
May 23, 20240.2 CNY/sh
Earnings
May 14, 2025

Profile

Guangdong Zhongsheng Pharmaceutical Co., Ltd. researches, develops, produces, and sells pharmaceutical products in China. The company offers Chinese and chemical medicines. It is also involved in the research and development of products in the fields of ophthalmology, cardiovascular, cerebrovascular, respiratory, digestive, diabetes, tumor, and senile degenerative diseases. The company was founded in 1979 and is based in Dongguan, China.
URL
http://www.zspcl.com/
IPO date
Dec 11, 2009
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
2,610,550
-2.45%
2,676,152
10.17%
Cost of revenue
2,120,844
2,138,721
Unusual Expense (Income)
NOPBT
489,706
537,431
NOPBT Margin
18.76%
20.08%
Operating Taxes
33,756
52,954
Tax Rate
6.89%
9.85%
NOPAT
455,950
484,477
Net income
263,273
-18.25%
322,050
16.00%
Dividends
(171,534)
(161,782)
Dividend yield
1.30%
0.74%
Proceeds from repurchase of equity
(2,635)
BB yield
0.02%
Debt
Debt current
621,488
612,155
Long-term debt
100,905
294,040
Deferred revenue
132,669
55,568
Other long-term liabilities
636,308
434,680
Net debt
(1,732,660)
(362,156)
Cash flow
Cash from operating activities
190,614
63,070
CAPEX
(363,057)
Cash from investing activities
(762,909)
Cash from financing activities
841,718
357,604
FCF
149,592
73,633
Balance
Cash
1,935,104
1,268,351
Long term investments
519,949
Excess cash
2,324,525
1,134,543
Stockholders' equity
2,406,852
2,681,313
Invested Capital
3,691,220
4,017,990
ROIC
11.83%
13.15%
ROCE
8.07%
10.29%
EV
Common stock shares outstanding
822,729
805,126
Price
16.05
-40.53%
26.99
123.24%
Market cap
13,204,795
-39.23%
21,730,343
125.40%
EV
11,641,508
21,481,911
EBITDA
612,207
637,000
EV/EBITDA
19.02
33.72
Interest
46,912
73,357
Interest/NOPBT
9.58%
13.65%